B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

1.560 +0.010 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,354
Open 1.560
Bid (Size) 1.570 (1)
Ask (Size) 1.600 (18)
Prev. Close 1.550
Today's Range 1.530 - 1.610
52wk Range 0.6181 - 1.880
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial
Via Investor Brand Network
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
From FSD Pharma Inc.
Via Business Wire

Performance

YTD
+102.07%
+102.07%
1 Month
-13.81%
-13.81%
3 Month
+101.29%
+101.29%
6 Month
+73.35%
+73.35%
1 Year
+87.95%
+87.95%

More News

Read More
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock
Via Investor Brand Network
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
From FSD Pharma Inc.
Via Business Wire
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video
Via Investor Brand Network
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington
Via Investor Brand Network
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum
Via Investor Brand Network
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance
Via Investor Brand Network
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
From FSD Pharma Inc.
Via Business Wire
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
Via Investor Brand Network
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
Via Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial
Via Investor Brand Network
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial
Via Investor Brand Network
Exposures Product Safety
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
From FSD Pharma Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.